GLP-1 Receptor Agonists and Diabetic Kidney Disease

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most co...

Full description

Bibliographic Details
Authors: Górriz, José Luis, Soler, María José|||0000-0003-3621-0766, Navarro-González, Juan F.|||0000-0002-5015-7474, García-Carro, Clara|||0000-0002-5130-603X, Puchades, María Jesús, D'Marco, Luis|||0000-0003-0148-891X, Martínez Castelao, Alberto|||0000-0003-3889-5578, Fernández-Fernández, Beatriz, Ortiz, Alberto|||0000-0002-9805-9523, Górriz-Zambrano, Carmen, Navarro Pérez, Jorge|||0000-0001-7414-7126, Gorgojo Martínez, Juan José|||0000-0002-8679-0968
Format: article
Publication Date:2020
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:252525
Online Access:https://ddd.uab.cat/record/252525
https://dx.doi.org/urn:doi:10.3390/jcm9040947
Access Level:Open access
Keyword:Chronic kidney disease
Diabetic kidney disease
GLP-1
Description
Summary:Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin-angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.

Similar Items